943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial
Feagan, B.G, Rutgeerts, P.J, Sands, B.E, Colombel, J, Sandborn, W.J, Hanauer, S.B, Van Assche, G.A, Axler, J, Kim, H, Danese, S, Fox, I, Milch, C, Sankoh, S, Wyant, T, Xu, J, Parikh, A
Published in Gastroenterology (New York, N.Y. 1943) (01.05.2012)
Published in Gastroenterology (New York, N.Y. 1943) (01.05.2012)
Get full text
Journal Article
OA05.01 Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy
Hellmann, M., Jänne, P., Opyrchal, M., Hafez, N., Raez, L., Gabrilovich, D., Wang, F., Ordentlich, P., Brouwer, S., Sankoh, S., Schmidt, E., Meyers, M., Ramalingam, S.
Published in Journal of thoracic oncology (01.10.2018)
Published in Journal of thoracic oncology (01.10.2018)
Get full text
Journal Article
Neo/adjuvant ADT to EBRT: Randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC)
Dearnaley, D., Saltzstein, D.R., Sylvester, J.E., Karsh, L., Mehlhaff, B.A., Pieczonka, C., Bailen, J.L., Maclean, D.B., Sankoh, S., Faessel, H.M., Lin, H.M., Shore, N.D.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
P501 Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders
Feagan, B., Sandborn, W.J., Smyth, M., Sankoh, S., Parikh, A., Fox, I.
Published in Journal of Crohn's and colitis (01.02.2014)
Published in Journal of Crohn's and colitis (01.02.2014)
Get full text
Journal Article
No association between vedolizumab exposure and serum JC virus levels
Parikh, A, Fedyk, E, Clifford, D, Berger, J, Sankoh, S, Paolino, J, Fox, I, Milch, C
Published in Inflammatory bowel diseases (01.01.2011)
Published in Inflammatory bowel diseases (01.01.2011)
Get full text
Journal Article
P323 Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trial
Sandborn, W., Sands, B., Rutgeerts, P., Sankoh, S., Rosario, M., Milch, C., Fox, I.
Published in Journal of Crohn's and colitis (01.02.2013)
Published in Journal of Crohn's and colitis (01.02.2013)
Get full text
Journal Article
P592 A phase 1, double-blind placebo-controlled single-dose study to determine the immune response to systemic and mucosal antigenic challenge in the presence of vedolizumab
Wyant, T., Leach, T., Sankoh, S., Wang, Y., Paolino, J., Feagan, B., Parikh, A.
Published in Journal of Crohn's and colitis (01.02.2013)
Published in Journal of Crohn's and colitis (01.02.2013)
Get full text
Journal Article
Phase I study of TAK-285, an investigational HER2/EGFR inhibitor, in patients (pts) with advanced cancer: Updated results and assessment of human CSF distribution
Chiorean, E. G., Sausville, E. A., Heath, E. I., Weise, A., Gomez-Navarro, J., Venkatakrishnan, K., Sankoh, S., Wu, J., Corvez, M., LoRusso, P.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
P164 - Clinical pharmacology of vedolizumab (MLN0002) in patients with active ulcerative colitis
Scholz, C., Wyant, T., Leach, T., Sankoh, S., Mould, D.R., Patella, M., Parikh, A., Fox, I., von Moltke, L.
Published in Journal of Crohn's and colitis (01.02.2009)
Published in Journal of Crohn's and colitis (01.02.2009)
Get full text
Journal Article